AzTrials
AzTrials

Systemic Inflammatory Response SyndromeEarly Phase 1NCT01592526

Autonomic Nervous Activity During the Systemic Inflammatory Response in Trained and Untrained Healthy Volunteers

A Early Phase 1 study testing Endotoxin and Endotoxin + Nicotine in people with Systemic Inflammatory Response Syndrome, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Critical illness, severe infection, extensive trauma or tissue damage cause an inflammatory (irritative) reaction in the body. This reaction affects the whole body and causes malaise, circulatory and cardiac changes, fever, increases the number of white blood cells in the blood stream and prompts release of signaling… Read more about this study

Who is it for?
Ages 18 to 35 years, men onlyHealthy volunteers can take part
Conditions the study is for
Systemic Inflammatory Response Syndrome
What is being tested?
Endotoxin and Endotoxin + Nicotine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
23 participants
Where
1 siteDenmark
Study dates
Jun 2012to Dec 2015
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Male
  • Age 18-35 years
  • BMI < 30 kg/m2
  • Healthy
  • Well-trained (N = 12): VO2max > 60 ml/kg/min
  • Untrained (N = 12): VO2max < 47 ml/kg/min

Who cannot join

  • Daily medicine intake (excl. antihistamines during pollen season)
  • Smoking or use of nicotine substitutes
  • Previous allergic reaction to nicotine pads
  • Previous splenectomy

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Center for Inflammation and Metabolism, Rigshospitalet

    Copenhagen, Copenhagen OE, 2100

Other trials in Denmark

About this study

Critical illness, severe infection, extensive trauma or tissue damage cause an inflammatory (irritative) reaction in the body. This reaction affects the whole body and causes malaise, circulatory and cardiac changes, fever, increases the number of white blood cells in the blood stream and prompts release of signaling proteins. This reaction contributes to the development of considerable organ damage and possibly organ failure. These are serious complications in critical illness which are associated with a high mortality. This inflammatory reaction is affected by the autonomic nervous system. This is the part of the nervous system, which is beyond the control of the free will, and the part that regulates circulation, breathing and digestive functions. The autonomic nervous system works via so-called sympathetic signals, which set the body in a state of alertness to overcome immediate challenges, and parasympathetic (vagal) signals, which are especially active during restitution and rest. It is known, that the balanced activity in the autonomic nervous system affects the body's inflammatory response in critical illness. A study in mice has shown that if parasympathetic (vagal) signals are blocked mortality in critical illness is increased. Reversely, when the autonomic nervous system is medically stimulated towards parasympathetic signaling, the magnitude of the inflammatory response is decreased. Nicotine exerts this stimulatory effect.

Also, we know that individuals in good physical shape have increased parasympathetic tone compared to less trained individuals. However, studies have never addressed whether this shifted balance in the autonomic nervous system affects the inflammatory response related to critical illness.

Read more

Over the last 30 years an experimental model mimicking the inflammatory response has been used in studies. Inflammation may be simulated by injecting the drug E.Coli LPS, which induces a controlled, fully reversible, harmless reaction the duration of which is a few hours. Influenza-like symptoms occur and changes in circulatory parameters and concentrations of signaling proteins can be measured.

Using this experimental model, the investigators wish to study whether this shifted balance in the autonomic nervous system in individuals in good physical shape affects the body's reaction to critical illness. Investigators also want to determine how nicotine (using a nicotine patch) affects this reaction.

Read the detailed description

Aim

The investigators wish to study the inflammatory response in very well-trained and relatively untrained healthy volunteers using the human endotoxemia model. Also, the investigators wish to study the effect on nicotine on the inflammatory response..

Background

  1. Systemic inflammation and the endotoxin model Inflammation is the organisms response to invasion of microorganisms, trauma, endogenic or exogenic tissue damage. Systemic inflammation is a generalized response which affects the entire organism and presents with symptoms (malaise, shivering, dizziness, nausea), clinical manifestations (fever, tachypnea and hypocapnia, tachycardia) and biochemical findings such as altered numbers and relative composition of leucocytes in blood and increased concentrations of acute phase reactants and cytokines. Systemic inflammation, activated cascades and microcirculatory disruptions are considered important pathogenic elements ind the development of organ dysfunction, which is a frequent and serious complication to critical illness regardless of the underlying cause. Over the last 30 years the human endotoxemia model has been us as an experimental platform for studies of systemic inflammation. Since the year 1998 studies using this model have been conducted at Center for Inflammation and Metabolism (CIM), Rigshospitalet, Copenhagen University Hospital. An IV-bolus or infusion of E.Coli-lipopolysaccharide (LPS), an isolated component of the outer cell wall of Gram-negative bacteria, also referred to as endotoxin, is administered to healthy volunteers. A dose-dependent, fully reversible response is evoked the duration of which is a few hours with flu-like symptoms and production of pro- and anti-inflammatory markers, e.g tumor-necrosis-factor-α (TNF), interleukin(IL)-1β, IL-6, IL-1ra and IL-10. Serious adverse events have not been observed. The model is no accurate replication of acute infection, sepsis or other critical illness, however, evokes a reproducible, inter-individually comparable and fully reversible inflammatory response, which allows experimental studies of early stages of acute systemic inflammation and the interplay between different aspects of critical illness complicated by systemic inflammation.
  2. The autonomic nervous system and the inflammatory response Activity in the autonomic nervous system affects the inflammatory response. Vagal stimulation inhibits release of pro-inflammatory cytokines, TNF-α, IL-1, IL-6 and high mobility group box protein-1 (HMGB-1), from macrophages activated by endotoxin, however, does not inhibit anti-inflammatory IL-10. Cytologic studies document, that this effect is mediated via the nicotinergic α7-subtype acetylcholine-receptor (α7nAchR). In a murine model peripheral vagal stimulation in vivo decreased mortality in endotoxemia and sepsis by cecal ligation. Kox et al found, that GTS-21 - a specific α7nAchR-agonist - was not generally associated with an altered inflammatory response in human endotoxemia, however, identified negative correlation between plasma concentrations of GTS-21 in the intervention group and maximal TNF-concentration. In another study, transdermally administered nicotine in healthy volunteers reduced the clinical, inflammatory response with reduced changes in body temperature and heart rate and increased plasma concentrations of cortisol and the anti-inflammatory IL-10. No differences in TNF-α, IL-1 or IL-6 expression were detected.
  3. Heart rate variability Heart rate variability (HRV) is the variation in the interval between successive heart beats over time. It is a well-described phenomenon and is believed to reflect the cardiac balance of sympathetic- and vagal activity, thus changes in HRV may be interpreted as an indirect marker of changes in autonomic nervous activity. Physiological or pathological changes in autonomic nervous activity can be observed with performance of a standardized valsalva maneuver while monitoring blood pressure, heart rate and subsequent calculation of HRV and blood pressure variability. Reduced HRV is present in critical illness and is believed to reflect a shift in autonomic nervous balance towards increased sympathetic activity and vagal withdrawal. This phenomenon is a well documented predictor for poor outcome. Equally, reduced heart rate variability is observed in human endotoxemia in healthy volunteers. However, the magnitude of this reduction in HRV does not correspond to the severity of the inflammatory response as determined by plasma concentrations of pro-inflammatory cytokines. Individuals in excellent training status present altered activity in the autonomic nervous system with increased vagal activity with a low resting heart rate and increased HRV. Whether this altered autonomic activity still presents during critical illness is unknown, but it is a possibility that certain positive effects of physical activity may in part be due increased vagal activity and alterations in the systemic inflammatory response mediated by the vagal activity.
  4. Exercise and the inflammatory response

No previous in vivo studies address the impact of increased vagal activity in well-trained individuals on the inflammatory response in comparison to that seen in untrained individuals. In the above mentioned study by Jan et al analysis of baseline HRV found that and HRV component traditionally considered proportional to sympathetic activity (LF/HF) correlated inversely with maximal TNF-α concentration in plasma. Furthermore, this study finds that heart rate at baseline does not correlate to HRV characteristics neither at baseline nor during endotoxemia. However, physical training condition of the participants is not reported.

Likewise, no mention of physical training status is made in the before mentioned studies concerning experimental use of nicotinergic agonist in endotoxemia (transdermally administered nicotine29 or orally administered GTS-21).

Two in vitro trials perform whole blood stimulation with LPS and find that baseline HRV is inversely proportional to TNF and IL-6 production, and inflammatory response in vitro is reduced in previously untrained individuals after a period of regular aerobic exercise. No in vivo studies addressing this have been conducted.

The investigators aim to study the inflammatory response in endotoxemia in well-trained and untrained healthy volunteers and determine whether transdermally administered nicotine alters this response.

A cross-over study design is applied so that volunteers act as their own control. This increases the chances of demonstrating a statistically significant effect.

Due to risk of LPS-tolerance the two study days need to be at least 4 weeks apart.

Hypotheses

  1. Healthy well-trained individuals produce a reduced inflammatory response during experimental endotoxemia compared to untrained individuals.
  2. Healthy, well-trained individuals display an increased HRV at baseline and experience a smaller reduction in HRV during endotoxemia compared to untrained individuals.
  3. Transdermally administered nicotine during endotoxemia reduces clinical and preclinical features of the inflammatory response during endotoxemia in well-trained as well as untrained individuals.
  4. Endotoxemia induces a transitory state of hyperalgesia in well-trained as well as untrained volunteers.
Being tested
Endotoxin, Endotoxin + Nicotine
Keywords
Systemic inflammatory response., Autonomic nervous regulation., Cholinergic antiinflammatory pathway
Medical subject headings
Systemic Inflammatory Response Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EndotoxinOther

    Also called Clinical Center Reference Endotoxin

    Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).

  • Endotoxin + NicotineOther

    Also called Clinical Center Reference Endotoxin, Nicotine Patch (Nicorette 15mg/16t)

    Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)

Study groups in NCT01592526
Study groupRoleWhat they receive
Untrained, healthy volunteers AExperimental(Endotoxin) before (Endotoxin + Nicotine)
Receives: Other: Endotoxin; Other: Endotoxin + Nicotine
Well-trained healthy volunteers AExperimental(Endotoxin) before (Endotoxin + Nicotine)
Receives: Other: Endotoxin; Other: Endotoxin + Nicotine
Untrained, healthy volunteers BExperimental(Endotoxin + Nicotine) before (Endotoxin)
Receives: Other: Endotoxin; Other: Endotoxin + Nicotine
Well-trained healthy volunteers BExperimental(Endotoxin + Nicotine) before (Endotoxin)
Receives: Other: Endotoxin; Other: Endotoxin + Nicotine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cytokines

    Cytokines are released into the bloodstream as part of the systemic inflammatory response and allow quantification of the severity of the systemic inflammatory response.

    Cytokines are measured multiple times to record changes from baseline during the intervention.

    Measured: up to 8 hours

Secondary outcomes (1)
  1. Heart Rate Variability (HRV)

    HRV is the variation in the interval between heart beats over a given time period. A higher variability is considered an indirectly marker of increasing vagal acitivity. Low variability contrarily indicates decreasing vagal activity and increased sympathetic activity.

    HRV is calculated from continous, non-invasive monitoring of heart rhytm. Recordings are made at multiple fixed times to track changes from baseline during intervention.

    Measured: up to 8 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 May 2012 (estimated)
  2. Study startJun 2012
  3. Primary completionJan 2013
  4. Study completionDec 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
23 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01592526
Sponsor's protocol ID
H-3-2012-011
Status last verified
Jan 2016
First submitted
2 May 2012
Last updated
29 Jan 2016
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Endotoxin and Endotoxin + Nicotine in people with Systemic Inflammatory Response Syndrome, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cytokines (time frame: up to 8 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in